Critical Survey: Calliditas Therapeutics AB (publ) (NASDAQ:CALT) and MindWalk (NASDAQ:HYFT)

Calliditas Therapeutics AB (publ) (NASDAQ:CALT) and MindWalk (NASDAQ:HYFT) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, profitability, risk, valuation and earnings.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Calliditas Therapeutics AB (publ) and MindWalk, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Calliditas Therapeutics AB (publ)	0	0	0	0	0.00
MindWalk	1	1	2	0	2.25

Risk and Volatility

Calliditas Therapeutics AB (publ) has a beta of 1.77, meaning that its stock price is 77% more volatile than the S&P 500. Comparatively, MindWalk has a beta of 0.58, meaning that its stock price is 42% less volatile than the S&P 500.

Insider and Institutional Ownership

2.8% of Calliditas Therapeutics AB (publ) shares are owned by institutional investors. Comparatively, 6.7% of MindWalk shares are owned by institutional investors. 2.2% of Calliditas Therapeutics AB (publ) shares are owned by company insiders. Comparatively, 6.8% of MindWalk shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares Calliditas Therapeutics AB (publ) and MindWalk’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Calliditas Therapeutics AB (publ)	-30.18%	-212.04%	-27.96%
MindWalk	-66.79%	-64.47%	-35.95%

Valuation & Earnings

This table compares Calliditas Therapeutics AB (publ) and MindWalk”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Calliditas Therapeutics AB (publ)	$1.60 billion	0.74	-$43.96 million	($1.85)	-21.62
MindWalk	$17.59 million	3.25	-$21.69 million	($0.60)	-2.07

MindWalk has lower revenue, but higher earnings than Calliditas Therapeutics AB (publ). Calliditas Therapeutics AB (publ) is trading at a lower price-to-earnings ratio than MindWalk, indicating that it is currently the more affordable of the two stocks.

Summary

MindWalk beats Calliditas Therapeutics AB (publ) on 9 of the 13 factors compared between the two stocks.

About Calliditas Therapeutics AB (publ)

Calliditas Therapeutics AB (publ), a commercial-stage bio-pharmaceutical company, focused on identifying, developing, and commercializing novel treatments in orphan indications with an initial focus on renal and hepatic diseases with significant unmet medical needs in the United States, Europe, and Asia. It offers Nefecon (TARPEYO/Kinpeygo), an oral formulation of budesonide to reduce the loss of kidney function in adults with immunoglobulin A nephropathy. The company's lead compound is Setanaxib, a NOX inhibitor that is in Phase 2b clinical trial for the treatment of primary biliary cholangitis; and in Phase 2 clinical trial for the treatment of squamous cell carcinoma of the head and neck cancer and idiopathic pulmonary fibrosis, as well as for solid tumors and Alport Syndrome. Calliditas Therapeutics AB (publ) was incorporated in 2004 and is headquartered in Stockholm, Sweden.

About MindWalk

ImmunoPrecise Antibodies Ltd., together with its subsidiaries, engages in antibody production and related services in the United States, Canada, Europe, and internationally. The company offers a range of antibodies, enzymes, enzyme activity assays, arthritis animal products, proteins, deiminated proteins, organoid growth factors, and hybridoma products for research purposes. Its services include custom antigen modeling, design, and manufacturing; B cell sorting, screening, and sequencing; custom, immune, and naive phage display production and screening; transgenic animals and multi-species antibody discovery; bi-specific, tri-specific, VHH, and VNAR (shark) antibody manufacturing; DNA cloning, protein and antibody downstream processing; antibody characterization on label-free biosensors and antibody engineering; transient and stable cell line generation; antibody optimization and humanization; hybridoma production with multiplexed, high-throughput screening, and clone-picking; and cryopreservation. The company has research collaboration agreements with Pierre Fabre S.A for antibody discovery; and Elektrofi, Inc. to explore a high-concentration formulation of COVID-19 antibody cocktail, PolyTope TATX-03. ImmunoPrecise Antibodies Ltd. was incorporated in 1983 and is based in Victoria, Canada.